Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment

Sulkowski M, Telep LE, Colombo M, Durand F, Reddy KR, Lawitz E, et al. Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment. Aliment Pharmacol Ther [Internet]. 2022;55(9):1169-1178. https://doi.org/10.1111/apt.16830

Publication Type:

Journal Article

Authors:

Sulkowski, M; Telep, LE; Colombo, M; Durand, F; Reddy, KR; Lawitz, E; BourliÃ¨re M; Cheinquer N; Scherbakovsky S; Ni L; Force L; Ramroth H; Gaggar A; Chokkalingam AP; Sise ME

Source:

Aliment Pharmacol Ther, Volume 55, Issue 9, p.1169-1178 (2022)

URL:

https://doi.org/10.1111/apt.16830

Keywords:

chronic kidney disease, dialysis, Direct-Acting Antiviral, End-stage Renal Disease, GS-331007, sofosbuvir

Cited On:

Patients with Renal Impairment

External Third-party Web Link:

https://pubmed.ncbi.nlm.nih.gov/35235245/

Export Citation:

RIS Format

Top